DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION				
158-15 Liberty Avenue	10/15/2020-10/23/2020*				
Jamaica, NY 11433	FEI NUMBER				
(718) 340-7000 Ext:5301 Fax:(718)662-5661	2000044401				
ORAPHARM1_RESPONSES@fda.hhs.gov					
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED					
Mr. Ankur J. Shah, President					
FIRM NAME	STREET ADDRESS				
Velocity Pharma LLC	210 Sea Lane				
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED				
Farmingdale, NY 11735-3900	Pharmaceutical Drug Repacker/ Relabeler				

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

OBSERVATION 1

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.

Specifically, the firm has not conducted product specific Filling Process Validation studies for each of the 3 drug products that they package and distribute (Aspirin, Acetaminophen, and Levocetirizine Dihydrochloride Tablets).

OBSERVATION 2

FORM FDA 483 (09/08)

PREVIOUS EDITION ORSOLETE

Written procedures are not established and followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

Specifically, the firm has not validated the equipment cleaning procedures, for the Tablet Filler/ Counter (b) (4), used to package Allergy Relief (Levocetirizine Dihydrochloride Tablets), Aspirin and Acetaminophen.

*DATES OF INSPECTION SEE REVERSE OF THIS PAGE EMPLOYEE(S) SIGNATURE Gam S Zamil , Investigator Gam S Zamil | Gam S Zamil | Investigator | Gam S Zamil | Investigator |

INSPECTIONAL OBSERVATIONS

PAGE 1 of 2 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES						
DISTRICT ADDRESS AND PHON	FOOD AND DRUG ADMINISTRAT		DATE(S) OF INSPECTION			
158-15 Libert			10/15/2020-10/23/2020*			
Jamaica, NY 1			FEI NUMBER 2000044401			
	7000 Ext:5301 Fax:(718)662-5661		2000011	101		
ORAPHARMI_KES	SPONSES@fda.hhs.gov					
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED						
Mr. Ankur J. Shah, President						
FIRM NAME						
Velocity Phar		210 Sea Lane				
CITY, STATE, ZIP CODE, COUNT			TYPE ESTABLISHMENT INSPECTED			
Farmingdale,	NY 11735-3900	Pharmaceutical Drug Repacker/ Relabeler				
10/15/2020(T 10/23/2020(F	hu), 10/16/2020(Fri), 10/19/20	020(Mon), 10	0/20/202	20(Tue), 10/21/	2020(Wed),	
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Gam S Zamil, Investigator			Carn S Zarmii Investigator Signed By: 2001625131 Date Signed: 10-23-2020 X 12:13:43	DATE ISSUED 10/23/2020	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE IN	SPECTIONAL O	BSERVATIO	ONS	PAGE 2 of 2 PAGES	